

Astrada *et al.*

Advancements in Managing Wound Biofilm: A Systematic Review and Meta-Analysis of Randomized Controlled Trials on Topical Modalities

Abstract

Running Title: Topical Modalities for Wound Biofilm

Adam Astrada, DHSc., CNS, RN^{1*}

Rian Adi Pamungkas, DPH, RN^{1,2}

Khoirul Rista Abidin, M. Biomed, RN^{3,4}

1. School of Nursing, Faculty of Health Sciences, Esa Unggul University, Indonesia

2. School of Nursing, University of Michigan, USA

3. Department of Medical Laboratory Technology, 'Aisyiyah Polytechnics Pontianak, Pontianak City, Indonesia

4. Department of Biotechnology, Postgraduate School, Padjadjaran University, Indonesia

*corresponding author:

Adam Astrada, DHSc., CNS, RN

Assistant Professor

School of Nursing, Faculty of Health Sciences, Esa Unggul University, Indonesia

Jl. Arjuna Utara No.9, Kebon Jeruk, Jakarta, Indonesia 11510

Email: adam.astrada@esaunggul.ac.id

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Significance: Gaining insights into the efficacy of topical wound treatments for biofilm eradication is pivotal to enhancing wound management strategies. Despite numerous available agents claiming anti-biofilm properties, the substantiating evidence remains inconclusive. This study aimed to assess the immediate impact of topical wound treatments on wound biofilm and healing outcomes in acute and chronic ulcers.

Recent Advances: We comprehensively searched PubMed, ClinicalTrials.gov, and Google Scholar. Additionally, eligible grey literature was incorporated. English-language randomized controlled trials, observational, cohort, and case-control studies targeting biofilm prevention, inhibition, or elimination across diverse wound types were included. Primary outcomes included biofilm presence and elimination, supplemented by secondary outcomes encompassing reduced wound size, complete closure, and diminished infection indicators. Bacterial load reduction and biofilm presence were also assessed.

Critical Issues: Twenty-eight articles met the inclusion criteria. Various modalities were identified, including biofilm-visualization techniques like wound blotting and handheld autofluorescence imaging. A notable high bias risk was observed across all studies. Pooled analysis for the primary outcomes was infeasible due to limited eligible studies and data reporting challenges. The primary source of bias is the lack of consensus on objectively evaluating the biofilm. As for the secondary outcomes, the pooled analysis for complete wound closure (6 RCTs, yielding $n=439$) and presence of infection/inflammation (2 RCTs, yielding $n=284$) showed no significant difference, with log odds ratio (LOD) 0.03 (95% CI: -1.02 – 1.09; $\tau^2=1.09$, SE: 1.10, $Q=14.33$, $p=.014$) and LOD -0.95 (95% CI: -3.54 – 1.64; $\tau^2=2.32$, $Q=2.71$, $p=.10$), respectively.

Future Direction: Our findings suggest insufficient evidence to support anti-biofilm claims of topical modalities. Clinicians' skill appears to play a pivotal role in biofilm elimination and wound healing enhancement, with potential optimization through visual-guided techniques like wound blotting and autofluorescence imaging. More rigorous clinical trials are warranted to ascertain the efficacy of these techniques.

Keywords: antibiofilm; wound biofilm; topical therapy; acute wound; chronic wound; dressing

55 1. Scope and Significance

56 Various products and approaches in the market claim to have antibiofilm effects, eventually
57 improving wound healing. Yet, the studies regarding this claim are inconclusive. This study
58 aimed to investigate the pooled effect of topical wound treatments on wound biofilm and
59 healing outcomes in acute and chronic ulcers.

60 2. Translational Relevance

61 This review found insufficient evidence to conclude that any topical modalities, namely
62 dressings, ointments, and wound bed preparation techniques, could reduce wound surface
63 biofilm across studies. The problem may be raised from the need for more consensus on the
64 objective evaluation of biofilm itself.

65 3. Clinical Relevance

66 The result further emphasizes the critical role of wound care clinicians' skills in wound biofilm
67 management instead of the types of products or topical modalities used.

68 4. Background

69 **Rationale**

70 Biofilm has become a growing health concern since it contributes to 80% of human
71 infections.¹ Microorganisms living within a biofilm are up to 1,000 times more antibiotic-
72 resistant than their planktonic forms.² Biofilm attached to indwelled devices, such as
73 implants, can cause early implant removal and surgical site infections. The absence of
74 vascularization in implants creates a potential dead space that fosters microbial attachment
75 and biofilm development. Biofilm-associated costs in wounds and surgery are estimated to
76 reach several 3.3 billion US dollars in European countries.³ Moreover, a growing health threat
77 by superbugs and multi-drug-resistant pathogens amplifies the need for therapeutic
78 modalities to tackle biofilms, especially those associated with wounds.

79 It is estimated that 78.2% of wounds present biofilms.⁴ Since biofilm is ubiquitous in wounds,
80 multi-modal approaches have been proposed and developed to combat this situation. More
81 than 40 agents available on the market in various forms claim to have anti-biofilm effects.⁵

Astrada *et al.*

Yet, the evidence supporting this claim remains unclear. Therefore, this systematic review and meta-analysis aimed to provide pooled data on topical wound treatments such as cleansers, ointment, dressings, and therapeutic modalities and their immediate effects on biofilm elimination and wound healing in acute and chronic ulcers.

5. Methods

The search strategy was based on the research question of "To patients with acute or chronic ulcers (participants), do the topical wound treatments such as cleansers, ointment, dressings, and therapeutic modalities (intervention) provide anti-biofilm effects or eliminate biofilms compared to the standard of care or among the products (comparators)." The review protocol is reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 and registered in PROSPERO 2023 (ID: CRD42023407421), available from: https://www.crd.york.ac.uk/prospERO/display_record.php?ID=CRD42023407421

5.1 Eligibility Criteria

We aimed to find, assess and synthesize all randomized controlled trials, observational studies (all types), cohort (longitudinal) studies, or case-control studies containing all types of wounds (e.g., acute and chronic wounds, such as diabetic foot ulcers, venous ulcers, surgical site infections, etc.) or clinical studies and trials (e.g., randomized controlled trials, non-controlled interventional studies, observational studies involving human subjects). If they used the following interventions wound dressings, ointments, or techniques purposed to prevent, inhibit, or eliminate wound biofilms.

If biofilm elimination; absence or reduced biofilm structures as observed microscopically, and reduced wound size was reported, we included it as the primary outcome, while if complete wound closure; healed or unhealed or reduced signs of infection; erythema, edema, warmth, pain, and dysfunction were reported, we included them as the secondary outcomes. We included clinical studies conducted in all wound care settings, including in-patient and ambulatory facilities. Non-clinical studies (e.g., in vitro, product development involving subjects without wounds) were excluded.

Astrada *et al.*

5.2 Participants

Included participants were: all types of wounds (e.g., acute and chronic wounds, such as diabetic foot ulcers, venous ulcers, surgical site infections, etc.) or clinical studies and trials (e.g., randomized controlled trials, non-controlled interventional studies, observational studies involving human subjects). Participants were excluded if the articles were published in languages other than English or studies not related to wound biofilms.

5.3 Interventions

Studies were eligible if they evaluated the use of wound dressing or ointment to prevent, inhibit, or eliminate wound biofilms.

5.4 Comparators

We included: any topical wound interventions (e.g., topical agents or wound dressings, including normal saline, iodine, honey, etc.) deemed as the standard of care or among the products.

5.5 Outcomes

Studies with the following primary outcomes were included: biofilm elimination, absence or reduced biofilm structures observed microscopically, or reduced wound size. Secondary outcomes were: complete wound closure: healed or unhealed, or infections or signs of infection: erythema, edema, warmth, pain, and dysfunction.

5.6 Setting

Studies were conducted in the following settings: all wound care settings, including in-patient and ambulatory facilities.

5.7 Study design

We included: randomized controlled trials, observational studies (all types), cohort (longitudinal) studies, cohort studies, or case-control studies. Only randomized controlled trials were included in the meta-analysis.

Astrada *et al.*

5.8 Search strategy

We included keywords (Appendix 1) in the search string MeSH or other subject terms, search filters, and text words. AA, a wound care expert, designed the search. The search was created with The Systematic Review Accelerator (<https://pubmed.ncbi.nlm.nih.gov/32004673/>).

Searches were done in PubMed, ClinicalTrials.gov, and Google Scholar with predefined keywords in MeSH terms. The dates searched were inception to 19th August 2022 (see Appendix 1). We restricted our initial search to exclude certain publication types. Conference abstracts, theses, articles in press, books or book chapters, and reviews did not appear in our search results. Only articles published in English were included. We manually checked the included studies' reference lists, performed a backward citation analysis, and had meta-analysis studies.

5.9 Study screening and selection

5.9.1 Screening

Screening by title and abstract was conducted by AA and KRA independently. After identification and abstract screening, full texts were retrieved for the remaining articles. Two authors (AA and RAP) reviewed the full texts against the inclusion criteria. Discrepancies were resolved by consensus. Figure 1 shows the PRISMA flow diagram for the selection process.




Figure 1. PRISMA Flow Diagram.

5.9.2 Data extraction

We used a data extraction form for study characteristics and outcome data, piloted in Two studies in the review. Two study's authors (AA & RAP) extracted the following data from included studies:

- types: randomized controlled trials, observational studies (all types), cohort (longitudinal) studies, cohort studies, case-control studies
- methods: study authors, year, study design, duration of follow-up, setting
- participants: number of participants, wound type(s)
- interventions and comparators: type of intervention, method of delivery, how the intervention was provided, frequency, type of comparator, no treatment, placebo, usual care
- outcomes: biofilm elimination; absence or reduced biofilm structures as observed microscopically (primary outcomes) or reduced wound size, complete wound closure; healed or unhealed or infections/signs of infection: erythema, edema, warmth, pain, and dysfunction; or bacterial load reduction (secondary outcomes). Table 1 describes the operational definition for each outcome.

Astrada *et al.*

175 Table 1. Operational definitions of the outcomes

Outcomes	Operational definition
Primary: Biofilm elimination (a)	Mean/median amount of biofilm
anti-	eliminated from the whole wound
biofilm	bed, as observed quantitatively and
effects	objectively.
Presence of biofilm (b)	Absence or reduced biofilm
	structures at least 50%, as observed
	microscopically; dichotomous:
	present or absent
Secondary: Reduced wound size/score (c)	Mean/median of planar wound size
wound	or score reduction by the end of the
healing	study
and Complete wound closure (d)	Complete epithelization,
infection	dichotomous: healed or unhealed
	Any presence of signs of infection:
Infection/signs of infection	erythema, edema, warmth, pain, and
(e)	dysfunction; dichotomous: present
	or absent
Bacterial load reduction (f)	Amounts of bacteria eliminated from
	the wound surface

176

177 5.9.3 Risk of Bias Assessment

178 Two review authors independently assessed the risk of bias for each study using
179 the Cochrane Risk of Bias 2 tool.

180 5.10 Data analysis

181 The treatment/intervention effect was measured in Comprehensive Meta-Analysis
182 v3.7. The treatment/intervention effect was calculated using log odds ratios (LOD) for

Astrada *et al.*

dichotomous outcomes. We undertook meta-analyses when at least two studies or comparisons reported the same outcome. We used a random effects model. The unit of analysis was individual patients. We did not contact investigators or study sponsors to provide missing data.

We used the τ^2 statistic to measure heterogeneity among the included trials. The publication bias / small studies effect was assessed using a Funnel plot.

We did not perform a subgroup analysis. Planned sensitivity analyses were: wounds receiving treatment for at least four weeks.

1916. Results

A total of 1,964 records were identified by the systematic search, including 207 relevant searches in Google Scholar, grey literature, and articles found via reference tracing. Of those, 1,935 were excluded after the title and abstract screening and assessment of the eligibility criteria, as shown in Figure 1.

Of 28 articles, there are 13 RCTs (yielding 1,058 subjects), 3 case series, 8 interventional studies without controls, 3 observational studies, and 1 proof-of-concept interventional study. These studies include types of wound post-surgical^{6,7}, venous⁸⁻¹¹, diabetic foot ulcers (DFUs)¹²⁻¹⁵, leg ulcers^{9,16-18}, pressure ulcers¹⁹⁻²¹, burns²², and unspecified chronic and acute ulcers^{10,23,32,24-31}.

Of the RCTs, types of topical treatment sought for its anti-biofilm properties include 4 studies that used wound irrigation solution such as poly-hexamethylene biguanide (PHMB)^{7,8,33} and sodium hypochlorite¹⁶, 3 studies that used antibiotics^{6,23,24}, 2 studies that used silver-based products^{9,10}, 4 studies that used gel-type ointments^{22,24} and Iodosorb® (cadexomer iodine, Smith and Nephew, USA)^{9,12}, 1 study that used negative pressure wound therapy with instillation¹⁶, and 2 studies that used the visual tool-guided wound cleansing^{13,14}. The summary of each eligible article is shown in Table 2.

Astrada *et al.*

6.1 Assessment of the Risk of Bias of the Included Studies

The risk of bias of all and individual RCTs is shown in Figures 2 and 3, respectively. All of the RCTs suggest a high risk (70%) of bias (Figure 2), primarily due to the detection bias and randomization process (selection bias) (Figure 3). Studies by Borges E *et al.* (2018) and Romanelli M *et al.* (2010) show a high risk of bias in all of the domains (Figure 3).




Figure 2. Risk of bias of all included RCTs.




Figure 3. Risk of bias of individual RCTs.

Astrada *et al.*

6.2 Anti-Biofilm Effects of the Treatments

As the first primary outcome, the biofilm elimination is reported in one RCT by Astrada (2021)¹³; three interventional studies without controls by Lenselink *et al.* (2011)²⁷ and Metcalf (2016 & 2020)^{28,29}; and two observational studies by Mori *et al.* (2019)²¹ and Koyanagi *et al.* (2021)²⁰ (Table 2). The meta-analysis was not feasible since only one study was found for each primary outcome.

Astrada *et al.* (2021) conducted a double-blinded randomized controlled trial in Indonesia. Patients with DFUs were treated with standard of care (SOC) along with wound-blotting guided biofilm debridement and antimicrobial dressings. The study demonstrated significant anti-biofilm effects, with the intervention group showing a mean \pm SD percentage of biofilm removed of $74.7\% \pm 5.33$ at week 1, compared to $53.6\% \pm 5.42$ in the control group ($p = 0.01$). By week 3, a significant reduction in the DMIST total score was observed in the intervention group (5.55 ± 0.33) compared to the control group (6.92 ± 0.33 , $p < 0.01$), indicating improved wound healing outcomes.

In the study by Lenselink *et al.* (2011), the patients were treated with Suprasorb X dressings containing PHMB. The study demonstrated that 63% of the patients showed "good reduction," and 32% showed "moderate reduction" in biofilm presence. Additionally, two studies by Metcalf *et al.* (2016 & 2020) investigated the effectiveness of AQUACEL™ Ag⁺ (ConvaTec Ltd. UK), a hydrofiber wound dressing containing ionic silver, metal chelating agent, and surfactant in addition to SOC on stagnant or deteriorating chronic ulcers in 4 weeks of intervention shows. In their year 2020's study, they found that the 'unwanted' wound bed tissue, assumed as harboring biofilm, changed from 92% to 40% (52% reduction). While in their 2016's study, they demonstrated a 31% reduction in the wounds showing biofilm presence.

The observational studies by Mori *et al.* (2019) and Koyanagi *et al.* (2021) also highlighted the use of the wound-blotting method to evaluate biofilm elimination. In a cross-sectional and retrospective study conducted in Japan by Mori *et al.* (2019), two studies evaluated the effectiveness of a biofilm-based wound care system in pressure ulcers. The intervention group showed significant anti-biofilm effects, with a higher

Astrada *et al.*

proportion of biofilm removal (65.2% vs. 38.9%, $p = 0.009$) and an increased likelihood of 90-day wound healing (adjusted HR: 4.5, 95% CI: 1.3 - 15.0, $p = 0.015$) compared to the control group.

The second primary outcome, biofilm presence, is reported only in one RCT by Borges *et al.* (2018)⁸ and one interventional studies without control by Lenselink *et al.* (2011)²⁷ (Table 2).

Borges *et al.* (2018) conducted an RCT in Brazil involving patients with venous leg ulcers. The intervention group received treatment with a PHMB cleansing solution, while the control group received a 0.9% NaCl solution. However, the study did not provide quantitative statistical findings on biofilm presence before and after treatment. Thus, the results regarding the effect of the intervention on biofilm presence are inconclusive.

Lenselink *et al.* (2011)²⁷, Metcalf *et al.* (2016 & 2020)^{28,29}, and Borges *et al.* (2018)⁸ evaluated the primary outcomes only by surrogate or clinical cues such as the presence of necrotic tissue or visible gel-like materials found on wound surface (Table 2). Astrada *et al.* (2021), Mori *et al.* (2019)²¹, and Koyanagi *et al.* (2021)²⁰ used the wound-blotting method to evaluate the primary outcomes (Table 2).

6.3 Wound Healing

For the secondary outcomes, the reduced wound size/score is reported in 6 RCTs^{9,10,13,14,24,33}, in 6 case series or non-controlled interventional studies^{11,19,26,27,31,34}, and 2 observational studies^{18,35}. However, the meta-analysis for this outcome could not be performed due to the poor data report³³, and data was ununifiable^{9,10,13,14,24}.

An RCT conducted by Romanelli *et al.* (2010) in Italy assessed the efficacy of Prontosan® wound irrigation solution compared to normal saline in treating chronic leg ulcers. After a 4-week, no significant difference in wound size reduction was observed between the groups.

In a 3-arm RCT conducted by Wolcott *et al.* (2015) in the USA, the effectiveness of different treatments on acute and chronic ulcers was evaluated. Arm-1 represented the control group, receiving SOC management. Arm-2 received Lipogel (Sanguitec gel, USA)

Astrada *et al.*

containing antibiofilm (hamamelitannin, xylitol, gallium) and antibiotics, and Arm-3 received SOC along with Lipogel containing personalized antimicrobial. The study included 15 subjects in each arm, and after four weeks of weekly debridement, Arm-3 demonstrated the most significant improvement in wound size reduction (72%) compared to Arm-1 (47%) and Arm-2 (62%), with statistical significance.

Two multicenter RCTs investigated silver-based products. Miller *et al.* (2010) conducted a multicenter RCT in Australia to compare the effects of nanocrystalline silver and cadexomer iodine treatments on lower leg ulcers, most of which were venous ulcers. After two weeks of treatment with antimicrobial dressings, the mean wound size reduction was $2.12 \pm 2.94 \text{ cm}^2$ in the silver group and $-0.22 \pm 8.18 \text{ cm}^2$ in the iodine group. In Belgium and the Netherlands, Beele *et al.* (2010) investigated the efficacy of silver alginate/carboxymethylcellulose dressing compared to non-silver calcium alginate fiber dressing in the venous leg and pressure ulcers. After a 4-week duration, the intervention group showed a wound size reduction of 11.9%, whereas the control group exhibited an increase of 31.7% ($p < .05$).

While in the same category of silver-based products, interventional studies without control by Walker *et al.* (2015), Metcalf *et al.* (2016), and Harding *et al.* (2016) investigated the effectiveness of AQUACEL™ Ag⁺ (ConvaTec Ltd. UK) in addition to SOC on stagnant or deteriorating chronic ulcers in 4 weeks of intervention. They found that the mean wound reduction ranged from 54% to 89%. Additionally, Francesco *et al.* (2022) investigated the use of cream containing SSD and hyaluronic acid in chronic wounds for four weeks. They found 65% wound size reduction (mean reduction 4.85 cm^2) in $80\% \pm 4\%$ of wounds, $p < .05$.

Two visual tool-guided RCTs were conducted by Astrada *et al.* (2021), and Rahma *et al.* (2022).¹⁴ Astrada *et al.* (2021)¹³ conducted a double-blinded RCT in Indonesia to evaluate the impact of wound-blotting guided biofilm debridement and antimicrobial dressings on DFUs compared to SOC. After a 3-week, there was no significant difference in absolute wound size reduction between the groups. However, the intervention group significantly reduced the DMIST³⁶ total score by week 3 ($p < .01$), indicating improved wound characteristics. While Rahma *et al.* (2022) conducted an RCT in the UK to assess, the efficacy of autofluorescence imaging-guided wound treatment using MolecuLight i:X

Astrada *et al.*

compared to SOC in DFUs. After 12 weeks, the intervention group exhibited a median percentage wound reduction of 91.3% (IQR=47.3–100%), while the control group had a median reduction of 72.8% (IQR=22.3-100%).

Antibiotic-based use is demonstrated in a within-group control case series conducted by Albaugh *et al.* (2013)¹⁸. They applied a 1-gram vancomycin-impregnated cellulose dressing on chronic wounds for three weeks. They showed mean \pm SD = 24.6% \pm 13.59 of wound size reduction in the intervention group, while in the control group, the size seems to increase by 14.5% \pm 71.91 ($p=.014$).

Furthermore, a Chinese Medicine-based product by Liu *et al.* (2019) is presented in a non-randomized controlled study on 60 pressure ulcers, 30 each for intervention and control groups. They investigated the application of paste containing lyophilized Yunnan Baiyao (YB Group Co. Ltd., China) aqueous extract in addition to debridement and 20 – 30 minutes of infrared therapy. After three weeks, they found a significant difference in wound size reduction in the intervention group mean difference of 4.1 cm².

While for the complete wound closure, it is reported in 8 RCTs^{6,7,9,10,12,14,23,24}, in 8 case series or non-controlled interventional studies^{11,17,25–28,30,34}, and 1 observational study³². Studies by Kim *et al.* (2018)²³ and Miller *et al.* (2010)⁹ were not included in the analysis because of the unreported number of events of the wounds reaching closure.

The six RCTs included in the pooled analysis yielding n=439, including the studies by Malizos *et al.* (2017)⁶, Malone *et al.* (2019)¹², Wolcott *et al.* (2015)²⁴, Beele *et al.* (2010)¹⁰, Ceviker *et al.* (2015)⁷, and Rahma *et al.* (2022)¹⁴.

Two antibiotic-based studies investigated this outcome by Malizos *et al.* (2017) and Wolcott *et al.* (2015). Malizos *et al.* (2017) conducted a multi-center RCT across Italy, France, and Belgium, focusing on surgical site post-osteosynthesis for closed fractures. The intervention group (n=126) used the coating of osteosynthesis implants with antibiotic-loaded hydrogel (DAC®), while the control group (n=127) received un-coated osteosynthesis implants. After two weeks, wound closure in the intervention group was 96.0% (121 of 126), while in the control group was 94.5% (120 of 127), $p=.76$; no significant difference was observed between groups. On the other hand, a study by Wolcott *et al.* (2015) found that groups receiving Lipogel in combination with antibiotics

Astrada *et al.*

and antibiofilm showed 80% to 93% of wounds achieved closure, while the control group only had 53%. However, there was no estimation of statistical difference provided.

The silver-based product study by Beele *et al.* (2010) also showed no significant difference between groups regarding wound closure.

Malone *et al.* (2019) conducted an RCT in Australia focusing on the effectiveness of a 6-week vs. 2-week treatment with Iodosorb® (cadexomer iodine, Smith and Nephew, USA) on DFUs. The study involved eight subjects in the intervention group and ten in the control group. After 12 weeks, the incidence of DFU complete closure was observed in 2 of 10 subjects (20%) in the intervention group, compared to 5 of 8 subjects (62.5%) in the control group. However, the difference between the groups was not statistically significant ($p=.145$).

Ceviker *et al.* (2015) conducted an open-label RCT focusing on coronary bypass post-surgical wounds in Turkey. The intervention group ($n=15$) received 0.5% PHMB (Actolind) for irrigation and topical application (soaked gauze), while the control group ($n=16$) received Ringer Lactate Solution (Neoflex) for irrigation and topical application (soaked gauze). After a 3-week, the complete wound closure was 66.7% (10 of 15) in the intervention group and 43.8% (7 of 16) in the control group, with significant differences between groups.

The visual-guided wound intervention study by Rahma *et al.* (2022) shows that by week 12, wounds receiving the autofluorescence imaging-guided wound treatment had the number of wounds healed 13 of 29 (45%, 95% CI 26–64%), while in the control group 6 of 27 (22.2%, 95% CI 9–42%). There was no statistical significance estimated.

Figure 4 shows a forest plot of the pooled random effects of 6 RCTs for this outcome with a log odds ratio (LOD) of 0.03 (95% CI: -1.02 – 1.09). The between-study heterogeneity variance was estimated at $\tau^2=1.09$ (SE: 1.10; $Q=14.33$, $p=.014$). The funnel plot of this outcome is shown in Figure 5.

Astrada *et al.*




Figure 4. Forest plot of the effect of intervention on complete wound closure.




Figure 5. Funnel plot of the included studies for the outcome of complete wound closure. Studies were sparse and asymmetrical which indicates those studies had high risk of bias.

Astrada *et al.*

6.4 Inflammation/Infection

The presence of inflammation/infection was reported in 4 RCTs^{6,7,10,22} and 1 non-controlled interventional study³¹. Of the 4 RCTs, 2 studies (Wattanaploy *et al.*, 2017 & Beele *et al.*, 2010) were not included in the meta-analysis due to reporting zero events of inflammation/infection in both groups, therefore giving no weight in the analysis. The pooled analysis yields n=284 from Malizos *et al.* (2017)⁶ and Ceviker *et al.* (2015)⁷ studies.

The use of coating of osteosynthesis implants with antibiotic-loaded hydrogel (DAC®) in a study by Malizos *et al.* (2017) showed a significant difference between groups where the incidence of inflammation/infection was 0% (0 of 126) in the intervention group. In contrast, the control group exhibited an incidence of 4.7% (6 of 127).

The treatment of PHMB-based products as an irrigation solution and topical application in the study by Ceviker *et al.* (2015) demonstrated that after a 52-week observation, the infection rate on coronary bypass post-surgical wounds, as identified by culture, was 40% in the intervention group and 37.5% in the control group. However, there was no significant difference between the groups ($p=0.886$).

The pooled estimate of this outcome for those studies is LOD -0.95 (95% CI: -3.54 – 1.64), while the between-study heterogeneity variance was estimated at $\tau^2=2.32$ ($Q=2.71$, $p=.10$) (Figure 6).




Figure 6. Forest plot of the effect of intervention on the presence of infection/signs of inflammation.

Astrada *et al.*

6.5 Bioburden

The effect of bacterial load reduction was reported in 4 RCTs^{8,12,16,23} and 5 case series or non-controlled interventional study^{15,17,25,30,31}. However, the pooled analysis of the RCTs was not feasible due to poor data report (Borges *et al.*, 2018 & Kim *et al.*, 2018)^{8,23} and ununifiable outcomes (Yang *et al.*, 2017 & Malone *et al.*, 2019)^{12,16}. The five case series were conducted by Gupta *et al.* (2019)²⁵, Patel *et al.* (2021)³⁷, Malone *et al.* (2021)¹⁵, Dryden *et al.* (2016)³⁰, and Francesco *et al.* (2022)³¹.

Case series by Gupta *et al.* (2019)²⁵ and Patel *et al.* (2021)³⁷ studied the use of topical bacteriophage therapy isolated from different water sources (ponds, rivers, and sewers). Using a convenient sample of 20 and 48 chronic non-healing wounds, respectively, they showed that after a 2-week post-intervention, all wounds became sterile.^{17,25}

Malone *et al.* (2021)¹⁵ studied the application of surfactant gel Plurogel® in addition to the standard of care and showed that 7 of 10 wounds had a Log10 reduction in bioburden.

Dryden *et al.* (2016)³⁰ studied the application of Surgihoney RO™ (Matoke Holdings Ltd., UK), a pure honey-derived gel with enhanced reactive oxygen species, on acute and chronic ulcers. After four weeks of application, 98% of the wounds exhibited a bacterial load reduction as evaluated via semiquantitative culture, but no statistical significance estimation was provided.

While Francesco *et al.* (2022)³¹ utilized the topical application of hyaluronic acid in combination with silver sulfadiazine on complicated chronic wounds and showed a significant Log10 bacterial load reduction four weeks after the baseline.

7. Discussion

This systematic review and meta-analysis aimed to elucidate the effectiveness of various interventions in targeting biofilms and their impact on wound healing outcomes in clinical studies. According to our review, the effect of any intervention aimed at biofilm elimination and complete biofilm presence eradication could not be clarified due to the lack of clinical trials available. However, we could estimate its pooled effect on the secondary outcomes: complete wound closure and presence of inflammation/infection. Still, we found that all the

Astrada *et al.*

products claimed to have anti-biofilm properties showed no significant effect in achieving complete wound closure and reducing inflammation/infection compared to the control treatment.

Clinical trials we found involving techniques of visual-guided wound cleansing, including wound-blotting guided debridement and autofluorescence imaging camera; and wound care products, including silver-based products, PHMB dressing and irrigation solution, NPWT with instillation of sodium hypochlorite, cadexomer iodine, and antibiotic-impregnated gels. One interesting approach is using topical bacteriophage cocktail studies by Gupta *et al.* (2019)²⁵ and Patel *et al.* (2021)³⁷ in case series studies where the wound became sterile after the cocktail treatment. Although they did not evaluate the biofilm directly itself, this might suggest that the treatment might prevent the development of biofilm in the first place, showing the potential for further exploration in the future.

The problem with studies included in this review is that there needed to be more consensus on objectively evaluating the biofilm. Studies included in this review still rely on the conventional culture method or surrogate end-point, such as clinical signs and symptoms. Studies by Beele *et al.* (2010) use clinical signs and symptoms to identify biofilms, such as continuous pain, edema, warmth, moderate to heavy exudate, and the presence of slough at least 50% of the wound surface, foul odor, or necrotic plaques. Studies by Yang *et al.* (2017)¹⁶, Miller *et al.* (2010)⁹, and Wolcott *et al.* (2015)²⁴, were also claiming the evaluation of intervention on the biofilm matrix. However, these studies needed to present data regarding the objective evaluation of the biofilm's presence. Instead, they focused on the colony-forming unit count and explored its influence on wound healing. Only studies by Borges *et al.* (2018)⁸ and Malone *et al.* (2019 & 2021)^{12,15} reported objective evaluation of biofilm using scanning electron microscopy, DNA sequencing, and real-time quantitative polymerase chain reaction (qPCR). Yet this technique was used only to confirm the biofilm presence at the baseline, making the quantitative evaluation at the end of the intervention not possible. This finding alarms the need of consensus for the objective biofilm evaluation for future studies.

Using a visual-guided wound cleansing approach may offer a solution in the clinician's best interest more objectively. Techniques such as wound-blotting and autofluorescence-guided imaging may offer a promising approach for assessing biofilm presence and monitoring the effectiveness of interventions in real-time. The wound-blotting technique could visualize the

Astrada *et al.*

wound surface biofilm by attaching a piece of nitrocellulose membrane on wounds for 10 seconds, then stained by Alcian Blue to highlight parts of the wound that still harbor biofilms. This technique has a sensitivity of 100%, as shown in *in vivo* study.³⁸ An RCT by Astrada *et al.* (2021) and observational studies by Mori *et al.* (2019)²¹ and Koyanagi *et al.* (2021)²⁰ show that wound blotting could help clinicians to determine the effectiveness of wound cleansing in real-time as well as improving wound healing. While in The Fluorescence imaging Assessment and Guidance (FLAAG) study, a multi-center diagnostic accuracy study by Le *et al.* (2022)³⁹ on 350 patients with chronic wounds, shows that the autofluorescence imaging technique could detect $> 10^4$ CFU/g in 82% of biopsied wound tissue which mostly missed by direct inspection of the clinical signs and symptoms. The study shows this technique has moderate sensitivity (61,0%) but high specificity (84%).³⁹ A study by Rahma *et al.* (2022)¹⁴ is the first RCT to evaluate this technique, but it is still a pilot study. Regardless, this technique could change 69% of treatment plans, influenced 85% of wound bed preparation, and improved 90% of patient care by 20 clinicians in those centers.³⁹ Additionally, a study by Wu *et al.* (2022)³² attempted to compare both techniques, i.e., wound-blotting and autofluorescence imaging, in predicting healing in chronic wounds in 90 days. They found that wound blotting shows a significantly strong correlation coefficient of Kendall's tau value = 0.563, $p < .001$ to complete wound healing, while MolecuLight i:X Exhibited no significant association ($p = .184$). This indicates that wound blotting may be more beneficial for wound healing prognosis because the wound blotting detects the actual biofilms. In contrast, the autofluorescence bacterial visualization detects planktonic and biofilm forms but cannot distinguish between the two.³⁸ Future research is needed to focus on standardized methods for biofilm assessment and to assess the long-term effects of biofilm elimination on wound healing outcomes considering the clinical implications of biofilm elimination in improving patient well-being.

Finally, since we found no sufficient evidence supporting the antibiofilm effects of any available products or topical interventions, the skills of wound care clinicians seem to be the most critical factor in biofilm management. This may include the cleansing technique, locating the highly susceptible wound bed for biofilm development, exudate management, antimicrobial selection, and adherence to the timely dressing change. Visual-guided wound cleansing may open a new therapeutic approach to combat wound surface biofilm.

Astrada *et al.*

484

485 Limitations

486 There is a high risk of bias in almost all clinical trials included in the meta-analysis. The
487 primary source of bias is the lack of consensus on objectively evaluating the biofilm. There is
488 also the risk of selection bias because studies included in the pooled estimation did not
489 distinguish types of modalities due to the lack of eligible clinical trials.

490

491 8. Conclusion

492 This study indicates that there is currently inadequate evidence to support the claims of any
493 topical treatments having an anti-biofilm effect on the healing of acute and chronic wounds.
494 The skill of treating clinicians offers the main contribution in eliminating biofilm and
495 improving wound healing which can be optimized via visual-guided wound cleansing such as
496 wound blotting and autofluorescence imaging techniques. More rigorous clinical trial studies
497 are needed to clarify the benefit of those techniques.

498

499 9. Take-Home Messages

- 500 • Insufficient Clinical Backing for Anti-Biofilm Treatments: Despite claims, this analysis
501 highlights the scarcity of clinical trials supporting biofilm-targeting interventions in
502 wound healing, necessitating more substantial evidence.
- 503 • Key Clinician Skill in Biofilm Management: The proficiency of wound care practitioners
504 stands pivotal in biofilm control and wound healing, encompassing techniques,
505 antimicrobial choices, and dressing adherence.
- 506 • Visual-Guided Cleansing Shows Promise: Techniques like wound-blotting and
507 autofluorescence imaging offer potential in objectively assessing biofilm presence,
508 influencing real-time treatment decisions, and warranting further study for enhanced
509 wound healing.

510

Astrada *et al.*

511 10. Authors' Contributions

512 AA contributed to the design of this review. AA and KRA collect all data and screen data. AA
513 and RAP contributed to data verification and statistical analysis. AA made all figures and
514 tables. AA, RAP, and KRA contributed to the article writing. AA and RAP revised the article. All
515 listed authors checked and agreed to the final article.

516

517 11. Acknowledgement and Funding

518 This research received no specific grant from funding agencies in the public, commercial, or
519 not-for-profit sectors.

520

521 12. Author Disclosure and Ghostwriting

522 The authors declare that no conflict of interest might affect the integrity of this work. While
523 preparing this work, the authors used ChatGPT August 3 Version to improve the readability
524 of the text. After using this tool/service, the authors reviewed and edited the content as
525 needed and take full responsibility for the publication's content.

526

527 13. About the Authors

528 **Adam Astrada**, an assistant professor at Esa Unggul University and a national board
529 member of the Indonesian Wound Enterostomal and Continence Nurses Association, who
530 has received a Gold Prize from the Journal of Wound Care Awards 2023 for his works in
531 Advances in Infections and Biofilm. He has published 4 SCI, including 3 articles in the Journal
532 of Wound Care and 1 article in Enfermeria Clinica.

533 **Rian Adi Pamungkas**, an assistant professor and Head of the School of Nursing at Esa
534 Unggul University. He is also a postdoctoral scholar at the University of Michigan.

535 **Khoirul Rista Abidin** is a doctoral student in Biotechnology Study Program, at Padjadjaran
536 University. He is a Lecturer at the Department of Medical Laboratory Technology, Aisyiyah

Astrada *et al.*

537 Polytechnic Pontianak. He also works as a wound care clinician at Komamura Wound &
538 Obesity Care Center and Aisyyah Clinic Pontianak. His research interest is
539 noninfectious diseases.

540

541 14. Abbreviations and Acronyms

542 CI = confidence interval

543 DAC = defensive antibacterial coating

544 DFUs = diabetic foot ulcers

545 DMIST = depth, maceration, inflection/inflammation, size, tissue of wound bed, tissue of
546 wound edge, and tunneling/undermining

547 LOD = log odds ratio

548 MeSH = medical subject headings

549 NaCl = natrium chloride

550 NPWT = negative pressure wound therapy

551 PFU = plaque forming unit

552 PHMB = poly-hexamethylene biguanide

553 PRISMA= preferred reporting items for systematic reviews and meta-analyses

554 RCTs = randomized controlled trials

555 SD = standard deviation

556 SE = standard error

557 SOC = standard of care

558 TBSA = total body surface area

559 15. References

560 1. National Health Institute. Research on Microbial Biofilms. 2002. Available from:

Astrada *et al.*

- 561 <https://grants.nih.gov/grants/guide/pa-files/pa-03-047.html> [Last accessed:
562 9/3/2022].
- 563 2. Yan J, Bassler BL. Surviving as a Community: Antibiotic Tolerance and
564 Persistence in Bacterial Biofilms. *Cell Host Microbe* 2019;26(1):15–21; doi:
565 10.1016/j.chom.2019.06.002.
- 566 3. Hrynshyn A, Simões M, Borges A. Biofilms in Surgical Site Infections: Recent
567 Advances and Novel Prevention and Eradication Strategies. *Antibiotics*
568 2022;11(1):69; doi: 10.3390/antibiotics11010069.
- 569 4. Malone M, Bjarnsholt T, McBain AJ, et al. The prevalence of biofilms in chronic
570 wounds: a systematic review and meta-analysis of published data. *J Wound*
571 *Care* 2017;26(1):20–25.
- 572 5. Schwarzer S, James GA, Goeres D, et al. The efficacy of topical agents used in
573 wounds for managing chronic biofilm infections: A systematic review. *J Infect*
574 2020;80(3):261–270; doi: 10.1016/j.jinf.2019.12.017.
- 575 6. Malizos K, Blauth M, Danita A, et al. Fast-resorbable antibiotic-loaded hydrogel
576 coating to reduce post-surgical infection after internal osteosynthesis: a
577 multicenter randomized controlled trial. *J Orthop Traumatol* 2017;18(2):159–
578 169; doi: 10.1007/s10195-017-0442-2.
- 579 7. Ceviker K, Canikoglu M, Tatlioglu S, et al. Reducing the pathogen burden and
580 promoting healing with polyhexanide in non-healing wounds: A prospective
581 study. *J Wound Care* 2015;24(12):582–586; doi: 10.12968/jowc.2015.24.12.582.
- 582 8. Borges EL, Frison SS, Honorato-Sampaio K, et al. Effect of Polyhexamethylene
583 Biguanide Solution on Bacterial Load and Biofilm in Venous Leg Ulcers. *J*
584 *Wound, Ostomy Cont Nurs* 2018;45(5):425–431; doi:
585 10.1097/WON.0000000000000455.
- 586 9. Miller CN, Newall N, Kapp SE, et al. A randomized-controlled trial comparing

Astrada *et al.*

- 587 cadexomer iodine and nanocrystalline silver on the healing of leg ulcers.
588 Wound Repair Regen 2010;18(4):359–367; doi: 10.1111/j.1524-
589 475X.2010.00603.x.
- 590 10. Beele H, Meuleneire F, Nahuys M, et al. A prospective randomised open label
591 study to evaluate the potential of a new silver alginate/carboxymethylcellulose
592 antimicrobial wound dressing to promote wound healing. Int Wound J
593 2010;7(4):262–270; doi: 10.1111/j.1742-481X.2010.00669.x.
- 594 11. Harding KG, Szczepkowski M, Mikosiński J, et al. Safety and performance
595 evaluation of a next-generation antimicrobial dressing in patients with chronic
596 venous leg ulcers. Int Wound J 2016;13(4):442–448; doi: 10.1111/iwj.12450.
- 597 12. Malone M, Schwarzer S, Radzieta M, et al. Effect on total microbial load and
598 community composition with two vs six-week topical Cadexomer Iodine for
599 treating chronic biofilm infections in diabetic foot ulcers. Int Wound J
600 2019;16(6):1477–1486; doi: 10.1111/iwj.13219.
- 601 13. Astrada A, Nakagami G, Kashiwabara K, et al. Targeting Biofilms in the
602 Management of Diabetic Foot Ulcers through Wound Blotting-Guided
603 Visualization (ウンドブロッキングによる可視化に基づく バイオフィルムを
604 ターゲットとした糖尿病足潰瘍管理). The University of Tokyo; 2021.
- 605 14. Rahma S, Woods J, Brown S, et al. The Use of Point-of-Care Bacterial
606 Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot
607 Randomized Controlled Trial. Diabetes Care 2022;45(7):1601–1609; doi:
608 10.2337/dc21-2218.
- 609 15. Malone M, Radzieta M, Schwarzer S, et al. Efficacy of a topical concentrated
610 surfactant gel on microbial communities in non-healing diabetic foot ulcers
611 with chronic biofilm infections: A proof-of-concept study. Int Wound J
612 2021;18(4):457–466; doi: 10.1111/iwj.13546.
- 613 16. Yang C, Goss SG, Alcantara S, et al. Effect of Negative Pressure Wound Therapy

Astrada *et al.*

- 614 With Instillation on Bioburden in Chronically Infected Wounds. *Wounds a*
615 *Compend Clin Res Pract* 2017;29(8):240–246.
- 616 17. Patel DR, Bhartiya SK, Kumar R, et al. Use of Customized Bacteriophages in the
617 Treatment of Chronic Nonhealing Wounds: A Prospective Study. *Int J Low*
618 *Extrem Wounds* 2021;20(1):37–46; doi: 10.1177/1534734619881076.
- 619 18. Albaugh KW, Biely SA, Cavorsi JP. The effect of a cellulose dressing and topical
620 vancomycin on methicillin-resistant *Staphylococcus aureus* (MRSA) and Gram-
621 positive organisms in chronic wounds: a case series. *Ostomy Wound Manage*
622 2013;59(5):34–43.
- 623 19. Liu J, Cai M, Yan H, et al. Yunnan baiyao reduces hospital-acquired pressure
624 ulcers via suppressing virulence gene expression and biofilm formation of
625 *staphylococcus aureus*. *Int J Med Sci* 2019;16(8):1078–1088; doi:
626 10.7150/ijms.33723.
- 627 20. Koyanagi H, Kitamura A, Nakagami G, et al. Local wound management factors
628 related to biofilm reduction in the pressure ulcer: A prospective observational
629 study. *Japan J Nurs Sci* 2021;18(2):1–8; doi: 10.1111/jjns.12394.
- 630 21. Mori Y, Nakagami G, Kitamura A, et al. Effectiveness of biofilm-based wound
631 care system on wound healing in chronic wounds. *Wound Repair Regen*
632 2019;27(5):540–547; doi: 10.1111/wrr.12738.
- 633 22. Wattanaploy S, Chinaronchai K, Namviriyachote N, et al. Randomized
634 controlled trial of polyhexanide/betaine gel versus silver sulfadiazine for
635 partial-thickness burn treatment. *Int J Low Extrem Wounds* 2017;16(1):45–50;
636 doi: 10.1177/1534734617690949.
- 637 23. Kim D, Namen li W, Moore J, et al. Clinical Assessment of a Biofilm-disrupting
638 Agent for the Management of Chronic Wounds Compared With Standard of
639 Care: A Therapeutic Approach. *Wounds a Compend Clin Res Pract*
640 2018;30(5):120–130.

Astrada *et al.*

- 641 24. Wolcott R. Disrupting the biofilm matrix improves wound healing outcomes. J
642 Wound Care 2015;24(8):366–371; doi: 10.12968/jowc.2015.24.8.366.
- 643 25. Gupta P, Singh HS, Shukla VK, et al. Bacteriophage Therapy of Chronic
644 Nonhealing Wound: Clinical Study. Int J Low Extrem Wounds 2019;18(2):171–
645 175; doi: 10.1177/1534734619835115.
- 646 26. Walker M, Metcalf D, Parsons D, et al. A real-life clinical evaluation of a next-
647 generation antimicrobial dressing on acute and chronic wounds. J Wound Care
648 2015;24(1); doi: 10.12968/jowc.2015.24.1.11.
- 649 27. Lenseink E, Andriessen A. A cohort study on the efficacy of a polyhexanide-
650 containing biocellulose dressing in the treatment of biofilms in wounds. J
651 Wound Care 2011;20(11):534–539; doi: 10.12968/jowc.2011.20.11.534.
- 652 28. Metcalf DG, Bowler PG. Clinical impact of an anti-biofilm hydrofiber dressing in
653 hard-to-heal wounds previously managed with traditional antimicrobial
654 products and systemic antibiotics. Burn Trauma 2020;8:1–9; doi:
655 10.1093/BURNST/TKAA004.
- 656 29. Metcalf D, Parsons D, Bowler P. A next-generation antimicrobial wound
657 dressing: a real-life clinical evaluation in the UK and Ireland. J Wound Care
658 2016;25(3):132–138; doi: 10.12968/jowc.2016.25.3.132.
- 659 30. Dryden M, Dickinson A, Brooks J, et al. A multi-centre clinical evaluation of
660 reactive oxygen topical wound gel in 114 wounds. J Wound Care
661 2016;25(3):140–146; doi: 10.12968/jowc.2016.25.3.140.
- 662 31. De Francesco F, Riccio M, Jimi S. Contribution of Topical Agents such as
663 Hyaluronic Acid and Silver Sulfadiazine to Wound Healing and Management of
664 Bacterial Biofilm. Medicina (B Aires) 2022;58(6):835; doi:
665 10.3390/medicina58060835.
- 666 32. Wu Y, Lin Y, Yang H, et al. Point-of-Care Wound Blotting with Alcian Blue

Astrada *et al.*

- 667 Grading versus Fluorescence Imaging for Biofilm Detection and Predicting 90-
668 Day Healing Outcomes. *Biomedicines* 2022;10(5):1200; doi:
669 10.3390/biomedicines10051200.
- 670 33. Romanelli M, Dini V, Barbanera S, et al. Evaluation of the efficacy and
671 tolerability of a solution containing propyl betaine and polihexanide for wound
672 irrigation. *Skin Pharmacol Physiol* 2010;23(SUPPL. 1):41–44; doi:
673 10.1159/000318266.
- 674 34. Metcalf D, Parsons D, Bowler P. A next-generation antimicrobial wound
675 dressing: a real-life clinical evaluation in the UK and Ireland. *J Wound Care*
676 2016;25(3):132–138; doi: 10.12968/jowc.2016.25.3.132.
- 677 35. Mori Y, Nakagami G, Kitamura A, et al. Effectiveness of biofilm-based wound
678 care system on wound healing in chronic wounds. *Wound Repair Regen*
679 2019;27(5):540–547; doi: 10.1111/wrr.12738.
- 680 36. Oe M, Yotsu RR, Arisandi D, et al. Validity of DMIST for monitoring healing of
681 diabetic foot ulcers. *Wound Repair Regen* 2020;28(4):539–546; doi:
682 10.1111/wrr.12816.
- 683 37. Serena TE, Jalodi O, Serena L, et al. Evaluation of the combination of a biofilm-
684 disrupting agent and negative pressure wound therapy: A case series. *J Wound*
685 Care 2021;30(1):9–14; doi: 10.12968/jowc.2021.30.1.9.
- 686 38. Astrada A, Nakagami G, Minematsu T, et al. Concurrent validity of biofilm
687 detection by wound blotting on hard-to-heal wounds. *J Wound Care*
688 2021;30(Sup4):S4–S13; doi: 10.12968/jowc.2021.30.Sup4.S4.
- 689 39. Le L, Baer M, Briggs P, et al. Diagnostic Accuracy of Point-of-Care Fluorescence
690 Imaging for the Detection of Bacterial Burden in Wounds: Results from the
691 350-Patient Fluorescence Imaging Assessment and Guidance Trial. *Adv Wound*
692 Care 2021;10(3):123–136; doi: 10.1089/wound.2020.1272.

Astrada *et al.*

- 693 40. Miller CN, Carville K, Newall N, et al. Assessing bacterial burden in wounds:
694 comparing clinical observation and wound swabs. *Int Wound J* 2011;8(1):45–55;
695 doi: 10.1111/j.1742-481X.2010.00747.x.
- 696 41. Metcalf DG, Bowler PG. Clinical impact of an anti-biofilm Hydrofiber dressing in
697 hard-to-heal wounds previously managed with traditional antimicrobial
698 products and systemic antibiotics. *Burn Trauma* 2020;8:1–9; doi:
699 10.1093/burnst/tkaa004.

700

701 16. Appendix 1

702 16.1 Search Strategies

703 PubMed - run 17/8/2022

704

705 ("dressing"[Text Word] OR "occlusive dressing"[MeSH Terms] OR
706 "biological dressing"[MeSH Terms] OR "biological dressing"[Text Word] OR
707 "bandage"[Text Word] OR "bandage"[MeSH Terms] OR ("ointment"[Text
708 Word] OR "topical ointment"[Text Word] OR "anti infective agent"[MeSH
709 Terms] OR "topical"[Text Word] OR "mupirocin"[MeSH Terms] OR
710 "oxyquinolin"[MeSH Terms] OR "sulfacetamide"[MeSH Terms] OR "silver
711 sulfadiazine"[MeSH Terms] OR "silver protein"[MeSH Terms] OR
712 "proflavine"[MeSH Terms] OR "povidone iodine"[MeSH Terms] OR
713 "natamycin"[MeSH Terms] OR "ointment"[MeSH Terms] OR
714 "nitrofurazone"[MeSH Terms] OR "miconazole"[MeSH Terms] OR
715 "hydroxyquinoline"[MeSH Terms] OR "hydrogen peroxide"[MeSH Terms]
716 OR "hexylresorcinol"[MeSH Terms] OR "ethacridin"[MeSH Terms] OR
717 "econazole"[MeSH Terms] OR "chlorhexidine"[MeSH Terms] OR
718 "cetylpyridin"[MeSH Terms] OR "camphor"[MeSH Terms] OR
719 "benzethonium"[MeSH Terms])) AND ("antibiofilm"[Text Word] OR

Astrada *et al.*

720 ""biofilm*""[Text Word] OR ""biofilm*""[MeSH Terms] OR ""extracellular
721 polymeric substance matri*""[MeSH Terms]) AND (""wound*""[Text Word] OR
722 ""wounds and injuries""[MeSH Terms] OR ""wound infection""[MeSH Terms] OR
723 ""wound healing""[MeSH Terms] OR ""surgical wound infection""[MeSH Terms]
724 OR ""surgical wound""[MeSH Terms] OR ""ulcer*""[Text Word] OR ""foot
725 ulcer*""[MeSH Terms] OR ""skin ulcer*""[MeSH Terms] OR ""leg ulcer*""[MeSH
726 Terms] OR ""injur*""[Text Word] OR ""skin injur*""[Text Word] OR ""skin
727 injur*""[Text Word])

728 17. Figure Legends

729 Figure 1. PRISMA Flow Diagram.
730 Figure 2. Risk of bias of all included RCTs.
731 Figure 3. Risk of bias of individual RCTs.
732 Figure 4. Forest plot of the effect of intervention on complete wound closure.
733 Figure 5. Funnel plot of the included studies for the outcome of complete wound closure.
734 Studies were sparse and asymmetrical which indicates those studies had high risk of bias.
735 Figure 6. Forest plot of the effect of intervention on the presence of infection/signs of
736 inflammation.

Table 2. Summary of included studies

No	Author	Year of publication, article type	Country(es)	Samples (n, I/C)	Wound type(s)	Treatments		End-points, duration in weeks	Results
						Intervention	Control		
1	Malizos, K. <i>et al.</i> ⁶	2017, Multicenter RCT	Italy, France, and Belgium	126/127	Surgical site post-osteosynthesis is for closed fractures	Coating of osteosynthesis implants with antibiotic-loaded hydrogel (DAC®)	Un-coated osteosynthesis implants	(d) in 2 weeks (e) in 52 weeks;	(d) I= 96.0% (121 of 126), C= 94.5% (120 of 127), $p=.76$, no significant difference between groups (e) I= 0% (0 of 126), C= 4.7% (6 of 127), $p=.03$
2	Borges, E. <i>et al.</i> ⁸	2018, RCT	Brazil	22/22	Venous leg ulcer	PHMB cleansing solution	0.9% NaCl solution	(b) and (f) all in one time pre- and post-test	(b) the results of biofilm presence before and after treatment were not reported quantitatively

									(f) unable to determine due to poor report
3	Kim, D. <i>et al</i> ²³	2018, crossed-over RCT	USA	22/21 at initial enrolment, then 12 from control were crossed over, and final 34/21	Chronic recalcitrant wounds (type was unspecified)	Standard debridement + triple-antibiotic, maximum-strength ointment (Neosporin + pain relief, Johnson & Johnson, NJ)	Standard debridement + biofilm-disrupting wound gel (BlastX, Next Science, FL)	(c), (d), (f) in 12 weeks	(c) relative wound reduction from the baseline mean \pm SDI= 72% \pm 8%, C= 53% ($p<.01$) (d) I= 52%, C= 17%, ($p>.05$) (f) difference between the group was not reported
4	Yang, C <i>et al.</i> ¹⁶	2017, RCT	USA	10/10	Leg or foot ulcers size >40 cm ²	NPWT (VAC Ulta, KCI, USA) with instillation by sodium hypochlorite 0.125%	NPWT (VAC Ulta, KCI, USA)	(f) in 1 week	(f) I= 43% decrease ($P<.05$); C= 14% increase ($p=.46$)

5	Wattanaplo y, S <i>et al.</i> ²²	2017, RCT	Thailand	23/23	Partial- thickness burns sized > 10% TBSA	Polyhexanide/bet aine (0.1%/0.1%) gel (Prontosan Wound Gel X, B Braun, Germany)	Silver sulfadiazine cream	(e) 3 weeks	(e) I= 0, C= 0, no significant difference between groups
6	Romanelli, M <i>et al.</i> ³³	2010, RCT	Italy	20/18	Chronic leg ulcers, age > 8 weeks old, size < 100 cm ²	Prontosan® wound irrigation solution (B Braun, Germany), containing polyhexanide and propyl betaine	Normal saline	(c) 4 weeks	(c) no significant difference between groups, and the result is not reported appropriately (no figures or tables)
7	Malone, M <i>et al.</i> ¹²	2019, RCT	Australia	8/10	Diabetic foot ulcers (DFUs)	A 6-week treatment with Iodosorb® (cadexomer iodine, Smith and Nephew, USA)	A 2-week treatment with Iodosorb® (cadexomer iodine, Smith and Nephew, USA)	(d) & (f) 12 weeks	(d) I= 2 of 10 (20%), C= 5 of 8 (62.5%), $p=.145$, no significant difference between groups (f) I = 0.5 Log10 (± 0.71) 16s copies/mg; C= 0.35 Log10 (± 0.36) ($p=.71$), no significant difference between groups

8	Wolcott, R. ²⁴	2015, 3-arm RCT	USA	15/15/15	Acute and chronic ulcers	Arm-2 (Gel only): empiric gel Lipogel (Sanguitec gel, USA) containing antibiofilm (hamamelitannin, xylitol, gallium) and antibiotics	Arm-1: standard of care (SOC): management of host barrier to healing, weekly debridement	(c) & (d) in 4 weeks	(c) Arm-1= 47%, Arm-2= 62%, Arm-3= 72%, $p<.05$ (d) Arm-1= 53%, Arm-2= 80%, Arm-3= 93%, $p<.05$
						Arm-3: SOC + Lipogel containing personalized antimicrobial			
9	Miller, CN <i>et al.</i> ⁹ Miller, CN <i>et al.</i> ^{40*}	2010 & 2011, respectively; multicenter RCT	Australia	133/133	Lower leg ulcers (73.7% were venous ulcers)	Nanocrystalline silver, including: Acticoat®, Acticoat® absorbent, Acticoat 7®	Cadexomer iodine, including: Iodosorb® powder, Iodosorb®	(c) & (d) in 1 week on treatment, then followed non-antimicrobial dressing for 12 weeks	(c) Healing rate in 2-week: Silver= (Mean \pm SD) 2.12 \pm 2.94, Iodine= -0.22 \pm 8.18 (d) Iodine= 63%, Silver= 64%, $p>.05$

						(Smith & Nephew)	ointment (Smith & Nephew)		
10	Beele, H <i>et al.</i> ¹⁰	2010, multicenter RCT	Belgium and Netherland	18/18	Venous leg and pressure ulcers	silver alginate/carboxymethylcellulose dressing	nonsilver calcium alginate fiber dressing (Kaltostat, ConvaTec Ltd, UK)	(c), (d) & (e) in 4 weeks	(c) I= 11.9%, C= -31.7%, $p=.017$ (d) I= 3 of 18 (16.67%), C= 1 of 18 (5.56%) (e) I= 0, C= 0; no significant difference between groups
11	Ceviker, K <i>et al.</i> ⁷	2015, open-label RCT	Turkey	15/16	Coronary bypass post-surgical wounds	0.5% PHMB (Actolind, Abem Kimya Ltd. Sti. Istanbul, Turkey) for irrigation and topical application (soaked gauze)	Ringer Lactate Solution (Neoflex, Turktipsan Sag. Tic. A.S. Ankara, Turkey) for irrigation and topical application (soaked gauze)	(d) & (e) in 3 weeks	(d) I= 10 of 15 (66.7%), C= 7 of 16 (43.8%), $p=.181$, no significant difference between groups (e) Infection rate, identified by culture, I= 40%, C= 37.5%, $p=0.886$, no significant difference between groups

12	Astrada, A <i>et al.</i> ¹³	2021, double- blinded RCT	Indonesia	80/82	DFUs	SOC + wound- blotting guided biofilm debridement + antimicrobial dressings	SOC, including mechanical and/or sharp debridement + wound dressing at the discretion of the wound care nurse	(a) & (c) in 3 weeks	(a) Mean \pm SD of the percentage of biofilm removed, at week 1 in I= 74.7% \pm 5.33, C= 53.6% \pm 5.42, $p=.01$; at week 2, I= 71.6% \pm 6.18 and C= 52.0% \pm 6.32, $p=.03$ (c) there was no difference in absolute wound size reduction between groups, but there was a significant reduction of DMIST total score by week 3, with final total score I= 5.55 \pm 0.33 and C= 6.92 \pm 0.33, $p<.01$
13	Rahma, S <i>et al.</i> ¹⁴	2022, RCT	UK	29/27	DFUs	SOC + autofluorescence imaging-guided wound treatment using MolecuLight i:X (MolecuLight Inc.,	SOC, including sharp, nonsurgical debridement of callus and nonviable tissue; review of off-	(c) & (d) in 12 weeks	(c) By week-12, the median percentage wound reduction was I= 91.3% (IQR= 47.3– 100%) vs C= 72.8% (IQR= 22.3 - 100%)

						Canada) a handheld camera	loading; identification and treatment of infection; and assessment of perfusion with revascularization when clinically indicated		(d) By week 12, wounds healed were I= 13 of 29 ulcers (45%, 95% CI 26–64%), C= 6 of 27 (22.2%, 95% CI 9–42%)
14	Gupta, P <i>et al.</i> ²⁵	2019, case series	India	20	Chronic non-healing ulcers	Topical application of cocktail containing 3-bacteriophage (at a dose of 0.1 ml/cm ² concentration 10 ⁹ PFU/mL) isolated from different water sources (ponds, rivers,	-	(d) in 12 weeks and (f) in 2 weeks	(d) 7 of 20 (35%) wounds showed complete closure (f) 20 of 20 (100%) wounds became sterile

						and sewer) against <i>Staphylococcus aureus</i> , <i>Pseudomonas aeruginosa</i> , and <i>Escherichia coli</i>			
15	Patel, DR <i>et al.</i> ¹⁷	2021, case series	India	48	Full-thickness non-healing chronic leg or foot ulcers	Topical application of cocktail containing single or specific bacteriophages (at a dose of 500µL/cm ²)	-	(d) in 12 weeks and (f) in 2 weeks (5 to 7 applications of phage therapy)	(d) 39 of 48 (81.25) wounds showed complete closure (f) 47 of 48 (97.92%) wounds became sterile
16	Liu, J <i>et al.</i> ¹⁹	2019, non-randomized controlled study	China	30/30	Hospital-acquired pressure ulcers	Debridement, followed by 20 – 30 minutes of infrared therapy, and application of paste	Debridement, followed by 20 – 30 minutes of infrared therapy, and application	(c) in 3 weeks	(c) a significant difference in wound size reduction in the intervention group mean difference of 4.1 cm ² (<i>p</i> <.05)

						containing lyophilized Yunnan Baiyao (YB Group Co. Ltd., China) aqueous extract	of Vaseline gauze		
17	Walker, M <i>et al.</i> ²⁶	2015, multi- national multi-center non- randomized intervention al study without a control	Germany, Italy, the United Kingdom, and Portugal. Spain, Slovakia, Canada, Czech Republic, Netherland s, Sweden, Denmark, Poland	113	Slow, non- healing, or deteriorating chronic and acute ulcers (venous ulcer 52%, DFU 12%)	AQUACEL™ Ag+ (ConvaTec Ltd. UK) Hydrofiber wound dressing containing ionic silver, metal chelating agent, and surfactant for up to 4 weeks	-	(c) & (d) in 4 weeks	(c) 63% achieved at least 75% wound size reduction (d) 19 (17%) were healed completely

18	Lenselink, E & Andriessen, A ²⁷	2011, cohort study without a control	Netherlands	28 (16 complete d the study)	Non-healing infected and/or critically colonized ulcers	Suprasorb X + PHMB (lohmann & rauscher GmbH)	-	(a), (b), (c), & (d) in 24 weeks	(a) 10 of 16 (63%) had 'good reduction', 5 of 16 (32%) had 'moderate reduction', 1 of 16 (6%) had 'no reduction' of biofilm presence (b) 10 (63%) clinically judged had no biofilms (c) 61% of ulcers had mean \pm SD ulcer size reduction = $9.6 \pm 14.5 \text{ cm}^2$ (d) 12 (75%) were completely healed
19	Metcalf, DG & Bowler, PG ⁴¹	2020, retrospective cohort study without a control	UK	65 (biofilm-associated suspicion n= 37)	Deteriorating or stagnant (chronic) ulcers	Standard care + AQUACEL™ Ag+ Extra (ConvaTec Ltd. UK) Hydrofiber wound dressing	-	(a) & (d) in the mean of 4.2 weeks (range 1 – 11 weeks)	(a) 'unwanted' wound bed tissue (necrotic, slough, biofilm) changed from 92% to 40% (52% reduction)

						containing ionic silver, metal chelating agent, and surfactant			(d) 11 of 65 (17%) had complete wound closure
20	Metcalf, D; Parsons, D; & Bowler, p ²⁹	2016, cohort study without a control	UK & Ireland	29 ulcers from 28 subjects	Stalled or deteriorating ulcers	Standard care + AQUACEL™ Ag+ Extra (ConvaTec Ltd. UK) hydrofiber wound dressing containing ionic silver, metal chelating agent, and surfactant	-	(a), (c) & (d) up to 4 weeks	(a) A shift from mainly sloughy/ suspected biofilm (n= 22, 76%) to 13 (45%), yielding 31% biofilm reduction (c) 26 of 29 (89%), including those healed completely and those at least 75% closure (d) 10 (34%) healed completely
21	Malone, M <i>et al.</i> ¹⁵	2021, proof-of-concept interventional study	Australia	10	DFUs	SOC + surfactant gel Plurogel® (Medline Industries Inc., USA) + non-adherent absorbent	-	(f) in 6 weeks	(f) 7 of 10 (70%) showed reduction (mean ± SD) 0.8 Log10 16S copies ± 0.6; while 3/10 (30%) showed increase 0.6 Log10 16S copies ± 0.8

						dressing pad (Zetuvit, Hartmann Australia)			
22	Dryden, M <i>et al.</i> ³⁰	2016, multi- center intervention al study without control	England	114 ulcers from 104 subjects	Acute and chronic ulcers	Surgihoney RO™ (Matoke Holdings Ltd., UK), pure honey- derived gel with enhanced reactive oxygen species	-	(d) & (f) in 4 weeks (range 1 – 19 weeks)	(d) 24 of 114 (21%) completely healed (f) 39 of 40 (98%) wounds showed reduction of bacterial load by semi-quantitative culture (no numerical bacterial load data shown)
23	Harding, KG <i>et al.</i> ¹¹	2016, intervention al study without control	42 (clinically infected= 10 and non- clinically infected= 32)	UK & Poland	Chronic venous ulcers	AQUACEL™ Ag+ (ConvaTec Ltd., UK) hydrofiber wound dressing containing ionic silver, metal chelating agent, and surfactant for 4 weeks,	-	(c) & (d) in 8 weeks	(c) Mean ± SD wound reduction was 54.5% ± 42.8% (d) 5 of 41 (12.2%) healed completely

						followed by AQUACEL™ (ConvaTec Ltd., UK) hydrofiber wound dressing for another 4 weeks			
24	Francesco, FD; Riccio, M; & Jimi, S. ³¹	2022, intervention al study without control	80	Italy	Complicated chronic wounds	Gauze with cream or cream only, containing hyaluronic acid and silver sulfadiazine 1% (Fidia Farmaceutici, Abano Terme, Italy)	-	(c), (e), & (f) in 4 weeks	(c) A significant 65% wound size reduction (mean reduction 4.85 cm²) in 80% ± 4% of wounds, <i>p</i> <.05 (e) 75% wounds showed absence of inflammation from the baseline (f) Median bacterial load reduction from the baseline 4.5 log10 CFU/mL to 3.4 log10 CFU/mL, <i>p</i> <.05

25	Koyanagi, H <i>et al.</i> ²⁰	2020, multi-center observational study	34	Japan	Pressure ulcers	Topical ointments: iodine, prostaglandin E1, silver sulfadiazine; or dressings: hydrocolloid, foam/silicone, gauze.	-	(a) in 1 week	(a) application of iodine ointment in 10 of 34 (29.4%) shows correlation coefficient with biofilm proportion = -0.42 ($p=.02$)
26	Mori, Y <i>et al.</i> ²¹	2019, cross-sectional (study 1) and retrospective (study 2) studies	Study 1: 88/26 Study 2: 16/64	Japan	Pressure ulcers	SOC + biofilm-based wound care system: using wound blotting as a guide for biofilm evaluation + sharp and/or non-contact ultrasonic debridement	SOC, including sharp debridement and suitable wound dressing at the discretion of the physicians	Study 1: (a) & Study 2: (c) in 90 days	(a) Study 1, the proportion of biofilms removed, I= 65.2% (95% CI: 41.1 – 78.8%) and C= 38.9% (95% CI: 12.9 – 68.0%), $p=.009$ (c) Study 2, adjusted HR for 90-day wound healing (proportion healed) in the intervention group was 4.5 (95% CI: 1.3 – 15.0, $p=.015$)

						(Qoustic Wound Therapy System, Arobella Medical, LLC, Minnetonka, MN, USA) at ultrasonic waves of 35 kHz			
27	Albaugh, KW; Biely, SA; & Cavorsi, JP ¹⁸	2013, within-group control, case series	23/23	USA	Chronic lower leg ulcers (15/23, 652% were venous ulcers)	3-week treatment (prospective): SOC + 1-gram vancomycin-impregnated cellulose dressing	3-week pre-treatment (retrospective): SOC	(c) in 3 weeks	(c) Mean ± SD change wound surface area, I= -24.6% ± 13.59; C= +14.5% ± 71.91, <i>p</i> =.014
28	Wu, YF <i>et al.</i> ³²	2022, observational study, without control	53	Taiwan	Unhealed chronic ulcers (72% were due to diabetes and trauma)	The grading system of a modified alcian blue staining wound blotting, a biofilm	MolecuLight i:X (MolecuLight Inc., Canada), handheld autofluorescence imaging camera	(d) in 90-day	(d) The modified alcian blue wound blotting grading system shows a significantly strong correlation coefficient of Kendall's tau value = 0.563, <i>p</i> <.001, to complete wound healing. While MolecuLight i:X

visualization
method

exhibited no significant
association ($p=.184$)

*posthoc analysis of the RCT by Miller *et al.* (2010)

RCT= randomized controlled trial, I: intervention, C: control, DAC: Defensive Antibacterial Coating, PHMB: poly hexamethylene biguanide, DFUs: diabetic foot ulcers; NPWT: negative pressure wound therapy, SOC: standard of care; TBSA: total body surface area, PFU: plaque forming unit

- (a) Biofilm elimination
- (b) Presence of biofilm, dichotomous: present/absent
- (c) Reduced wound size/score
- (d) Complete wound closure
- (e) Infections/signs of infection, dichotomous: present/absent
- (f) Bacterial load reduction